Category: Against

  • Roche Launches Cobas SARS-CoV-2 Variant Test to Detect Emerging Coronavirus Mutations

    Shots: The company has launched the cobas SARS-CoV-2 variant set 1 test to detect spike mutations in virus variants including UK (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) The accurate detection and differentiation of SARS-CoV-2 mutations can aid in assessing the spread of circulating variants and monitor their potential impact on diagnostics, vaccines and therapeutics […]

  • CureVac Collaborate with UK Government to Develop Vaccines Against SARS-CoV-2 variants

    Shots: The collaboration combines expertise, resources and technology from both parties to develop and manufacture variant vaccines against SARS-CoV-2 variants. CureVac is expected to supply 50M doses of variant vaccines to the UK, following the regulatory approval The VTF and the CureVac will deploy mRNA platform to assess multiple SARS-CoV-2 variants and are expected to […]

  • Russia’s Sputnik V Demonstrates 92% Efficacy Against COVID-19

    Shots: The P-lll study involves assessing of Sputnik V vaccine vs PBO from 19,866 volunteers with COVID-19. The efficacy of the vaccine is 92% effective in fighting COVID-19 based on peer-reviewed late-stage trial results published in the lancet international medical journal Previous data from two-dose regimen of the vaccine based on two different viral vectors […]

  • Regeneron’s REGEN-COV Antibody Cocktail Confirms its Effectiveness Against UK and South Africa SARS-CoV-2 Variants

    Shots: REGEN-COV neutralizes the SARS-CoV-2 B.1.1.7 variants, identified in the UK & SA. The data was included in a bioRxiv paper and submitted for peer-reviewed publication on the changing resistance of SARS-CoV-2 variants to Ab neutralization REGEN-COV retained its neutralizing capability against the B.1.1.7 variant. The Ab cocktails also retained its potency against the B.1.351 […]

  • Grifols to Evaluate New Immunoglobulin Therapy Against COVID-19 in Spain

    Shots: The company to initiate the clinical trial assessing the safety and efficacy of its COVID-19 drug based on the Grifols’ immunoglobulin Gamunex-C and containing anti-SARS-CoV-2 polyclonal Abs from plasma donors who have recovered from the disease The study is expected to be initiated in Feb’2021. The treatment will be administered in primary care centers […]

  • Bayer Collaborates with CureVac for CVnCoV Against COVID-19

    Shots: Bayer to support the development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate, CVnCoV and will contribute its expertise and established infrastructure in numerous area Curevac will be the MAH for the product while Bayer will support CureVac with country operations within the EU and additional markets. Additionally, Bayer has an option […]

  • Moderna’s mRNA-1273 Receives the US FDA’s EUA Against COVID-19

    Shots: The US FDA has authorized EUA of mRNA-1273 vaccine against COVID-19 in individuals ≥18yrs. The delivery to the US govt. will begin imminently while Moderna will continue to gather additional data and plans to file BLA for full licensure in 2021 Allocation and distribution will be prioritized according to populations identified by the CDC’s […]

  • Pfizer & BioNTech Receives MHRA’s EUA for BNT162b2 Against COVID-19

    Shots: Pfizer & BioNTech reports that the MHRA in the UK has granted a temporary authorization for the EU for BNT162b2 against COVID-19. The distribution of vaccine will be prioritized according to the populations identified in guidance from the JCVI The MHRA’s decision is based on a rolling submission, including data from the P-III study, […]

  • Bharat Biotech Initiates P-III Study for Covaxin Against COVID-19

    Shots: Following the successful completion of the interim analysis from the P-I & P-II clinical trials of Covaxin, the company has received the DCGI approval to conduct a P-III study of its COVID-19 vaccine The study will assess Covaxin (6mcg, IM at an interval of 28days) vs PBO in ~26,000 volunteers in a ratio (1:1) […]

  • AstraZeneca Resumes P-III Study of AZD1222 Against COVID-19 in the US

    Shots: The US FDA authorizes the restart of the P-III clinical study in the US following the resumption of trials in other countries in recent weeks. The FDA reviewed all safety data from studies globally and concluded it was safe to resume the trial A voluntary pause across all global studies was triggered on Sept […]

  • Sanofi and Translate Bio to Advance MRT5500 into Clinical Study Against COVID-19

    Shots: The companies reported the preclinical results of MRT5500 demonstrating the potential of the vaccine in neutralizing the Abs against SARS-CoV-2. The two doses of MRT5500 induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients The preclinical data support the advancement of MRT5500 for clinical development. The companies anticipate the initiation of […]

  • AstraZeneca Initiates P-I Study of AZD7442 Against COVID-19

    Shots: The first participants have been dosed in a P-I trial of AZD7442 to assess safety, tolerability, and PK of the combination mAbs in up to 48 healthy participants aged 18-55 yrs. in the UK. The study is funded by DARPA If AZD7442 proves to be tolerated and has a favorable safety profile in the […]

  • Pfizer and BioNTech Elicits Strong T-cell Response in P-I/II Study Against COVID-19

    Shots: The companies reported that most advanced of four COVID-19 vaccine candidates from their BNT162 mRNA-based vaccine program demonstrated the ability to elicit high SARS-CoV-2 neutralizing titers following the second dose in an ongoing P-I/II study in Germany The results divulge that BNT162b1 candidate induced strong CD4+ and CD8+ T-cell responses. BNT162b1 elicits RBD-specific, interferon-g+, […]